Stock Events

E-Therapeutics 

GBX9
7
-GBX0.5-5.26% Wednesday 17:35

Statistics

Day High
0
Day Low
0
52W High
24
52W Low
0
Volume
2,594,424
Avg. Volume
933,935
Mkt Cap
56.39M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

2MayExpected
Q1 2023
Q3 2023
Q1 2024
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ETX.LSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Schwab U.S. Broad Market
SCHB
Mkt Cap0
Schrodinger operates in computational drug discovery, directly competing with E-Therapeutics' network-driven drug discovery approach.
Illumina
ILMN
Mkt Cap20.93B
Illumina provides sequencing and array-based solutions for genetic analysis, which is foundational to the kind of computational biology E-Therapeutics engages in.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is focused on gene editing, a cutting-edge area of biotech that competes for similar research attention and funding as E-Therapeutics' drug discovery platform.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine works on gene editing, directly competing in the innovative biotech space where E-Therapeutics operates, especially in novel drug discovery.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is another gene editing company, competing in the biotech innovation space, relevant to E-Therapeutics' focus on novel therapeutic discovery.
Beam Therapeutics
BEAM
Mkt Cap2.2B
Beam Therapeutics specializes in precision genetic medicines, competing in the cutting-edge area of biotech that overlaps with E-Therapeutics' innovative drug discovery methods.
Twist Bioscience
TWST
Mkt Cap2.53B
Twist Bioscience operates in synthetic biology, producing synthetic DNA that is foundational for biotech research, competing with E-Therapeutics in the broader biotech innovation space.
Pacific Biosciences of California
PACB
Mkt Cap373.36M
Pacific Biosciences offers sequencing systems, essential for the genetic analysis that underpins the computational drug discovery efforts of companies like E-Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap130.59B
Regeneron Pharmaceuticals is a biotech company that, while larger and more established, competes for market share in the innovative drug discovery and development space, relevant to E-Therapeutics' operations.

About

e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.
Show more...
CEO
Mr. Ahmad Ali Mortazavi
Employees
34
Country
GB
ISIN
GB00B2823H99
WKN
000A0M8VQ

Listings

US
ETXPF